Ozempic vs Zepbound: Where They Sit on the Agonist Spectrum

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The PlexusDx Education Hub explains GLP-1 therapies, weight-management protocols, and the genetic groundwork behind each metabolic decision. Browse the Peptides & GLP-1 library.

This overview is written independently. PlexusDx has no commercial relationship with the manufacturers of any product reviewed here.

Setting Ozempic beside Zepbound is a good way to see how the incretin category has widened from a single receptor target toward two and, in research, three. This overview places both products on that spectrum as of April 2026, walking through design, approvals, evidence, safety, cost, and the genetics that precede any prescription.

Where Ozempic and Zepbound sit in the lineup

Ozempic (semaglutide, Novo Nordisk) is a GLP-1 pathway compound, and Zepbound (tirzepatide, Eli Lilly) is a GIP/GLP-1 dual agonist. They mark two rungs of a category that keeps expanding, which is why understanding the surrounding lineup makes the pair easier to interpret than a straight two-way matchup.

One receptor, two receptors, three: the agonist spectrum

Tirzepatide is a GIP/GLP-1 dual agonist; semaglutide, liraglutide, and dulaglutide are GLP-1-selective receptor agonists; and retatrutide is an investigational GLP-1, GIP, and glucagon triple agonist that is not FDA-approved as of April 2026 and is not sold by PlexusDx. All approved agents engage the GLP-1 receptor and modulate gastric emptying, post-meal glucose, and satiety signaling.

Approvals from diabetes to obesity to sleep apnea

FDA approval tracks with indication: Ozempic (semaglutide) for type 2 diabetes in 2017; Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021; Rybelsus for type 2 diabetes in 2019; Mounjaro (tirzepatide) for type 2 diabetes in 2022; Zepbound (tirzepatide) for chronic weight management in 2023 and obstructive sleep apnea in adults with obesity in 2024; Trulicity in 2014; and Victoza in 2010.

Trial evidence across the programs

The supporting studies include STEP (semaglutide for weight management), SUSTAIN and SELECT (semaglutide for diabetes and cardiovascular outcomes), SURMOUNT and SURPASS (tirzepatide), SURMOUNT-OSA (tirzepatide for sleep apnea), LEAD and LEADER (liraglutide), and AWARD (dulaglutide). Head-to-head data exists for some pairings, including SUSTAIN 7 and SURPASS-2, though differing doses and endpoints keep per-trial reading the sound approach.

A uniform safety profile across the class

Every FDA-approved GLP-1 and GIP/GLP-1 agent carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies and is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects dominate the common side effects; rare serious events include pancreatitis, gallbladder disease, and dehydration-related kidney injury.

Understanding the list-price band

As of April 2026, list prices for the FDA-approved brands range roughly $815–$1,620 per month at U.S. list price (manufacturer published pricing). The band is wide because it spans multiple brands and indications, and actual out-of-pocket cost depends on insurance coverage, the FDA indication on the prescription, savings-card eligibility, and compounded-alternative availability through licensed pathways.

The genes that precede any prescription

Before a compound is ever chosen, biology sets the stage. Variants in FTO (appetite and adiposity set-point), GLP1R (the receptor every GLP-1 compound engages), MC4R (energy balance), and TCF7L2 (glucose homeostasis and GLP-1 secretion) map the metabolic terrain. These pathway-level variants describe your baseline; they do not predict response to any single medication.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before starting, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 — so a protocol decision starts from your biology.

Related reading on PlexusDx: Ozempic Cost without Insurance, Ozempic Medication, Cost of Ozempic Per Month, Cost of Ozempic.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, and this page covers the mechanism, evidence, and genetic context that inform any decision to use them. PlexusDx does not sell, prescribe, or recommend any other GLP-1 category peptide beyond semaglutide and tirzepatide, including dulaglutide, liraglutide, retatrutide, and cagrilintide. The Precision Peptide Genetic Test does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions about Ozempic and Zepbound

What does the agonist spectrum mean in practice?

It describes how many hormone receptors a compound engages. Ozempic acts on the GLP-1 receptor alone, Zepbound acts on both GIP and GLP-1, and investigational retatrutide adds glucagon for three targets. More targets is a design difference, not automatically a better outcome, and each agent is studied and approved on its own terms.

Is Zepbound newer than Ozempic?

Yes. Ozempic was FDA-approved for type 2 diabetes in 2017, while Zepbound was approved for chronic weight management in 2023 and for obstructive sleep apnea in 2024. Zepbound represents a later, dual-agonist entry in the category, though newer does not automatically mean more suitable for a given person.

Does the genetic test track the whole spectrum?

The Precision Peptide Genetic Test analyzes pathway-level variants such as FTO, GLP1R, MC4R, and TCF7L2 that underlie the entire GLP-1 pathway rather than one product. It does not predict response to Ozempic, Zepbound, or any medication; it describes the baseline biology that every compound on the spectrum has to act on.

Why is the price range so broad?

The roughly $815–$1,620 monthly band spans several brands and indications, so it reflects manufacturer pricing choices rather than a single product. Real cost depends on insurance coverage, the indication on the prescription, savings-card eligibility, and whether a compounded pathway is available for a particular compound.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.